MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Awad Mark M.; Oxnard Geoffrey R.; Jackman David M.; Savukoski Daniel O.; Hall Dimity; Shivdasani Priyanka; Heng Jennifer C.; Dahlberg Suzanne E.; Anne Pasi A. J.; Verma Suman; Christensen James; Hammerman Peter S.; Sholl Lynette M.

首页> 外文期刊>Journal of Clinical Oncology >MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

【24h】

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

机译：非小细胞肺癌中的MET外显子14突变与年龄和阶段相关的MET基因组扩增和c-Met过表达相关

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第7期|共13页
作者
Awad Mark M.; Oxnard Geoffrey R.; Jackman David M.; Savukoski Daniel O.; Hall Dimity; Shivdasani Priyanka; Heng Jennifer C.; Dahlberg Suzanne E.; Anne Pasi A. J.; Verma Suman; Christensen James; Hammerman Peter S.; Sholl Lynette M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J] . Awad Mark M., Oxnard Geoffrey R., Jackman David M., Journal of Clinical Oncology . 2016,第7期

机译：非小细胞肺癌中的MET外显子14突变与年龄和阶段相关的MET基因组扩增和c-Met过表达相关
2. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer [J] . Mark M. Awad Journal of Clinical Oncology . 2016,第8期

机译：非小细胞肺癌中MET外显子14突变介导的c-Met受体降解受损。
3. P3.02b-066 Phase II Trial of the C-Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy [J] . Paul Paik, Uz Stammberger, Rolf Bruns, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02B-066期间C-Met抑制剂紫红素在晚期肺腺癌中试验，在先前治疗失败后遇到外显子14跳过突变
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study [O] . Li Liu, Farhin Shaheed Kalyani, Haiyan Yang, 2021

机译：高级NSCLC患者患者的预后和同时基因组改变患者扩增或遇到EXON 14抑制抑制剂治疗的突变突变：回顾性研究
7. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [O] . Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, 2016

机译：在非小细胞肺癌中遇到外显子14突变与晚期和阶段依赖性的符合基因组扩增和C-MET过度表达有关

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

摘要

著录项

相似文献

相关主题

期刊订阅